Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 3, 2009, Pages 267-275

  Apuzzo, Linda G ^a   Vaida, Florin ^b   Gallant, Joel E ^a,c   Ernstrom, Karin B ^b   Little, Susan J ^b   Routy, Jean Pierre ^d   Collier, Ann C ^e   Conway, Brian ^f   Markowitz, Martin H ^g   Hecht, Frederick M ^h   Walker, Bruce D ⁱ   Connick, Elizabeth ^j   Margolick, Joseph B ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

Cohort studies; Regimen modification; Toxicity

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADULT; AGED; ANEMIA; ANXIETY; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FINGER TREMOR; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMSOMNIA; IRRITABILITY; JAUNDICE; LETHARGY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MOOD; NAUSEA; NIGHTMARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; COHORT ANALYSIS; MIDDLE AGED;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 63149103626     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181963ae6     Document Type: Article

References (68)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, January 29, 2008. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf Accessed August 15, 2008.
2. Smith DE, Walker BD, Cooper DA, et al. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS. 2004;18:709-718.
3. Blankson JN. Primary HIV-1 infection: to treat or not to treat? AIDS Read. 2005;15:245-251.
4. Kassutto S, Maghsoudi K, Johnston MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006;42:1024-1031.
5. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005;191:1410-1418.
6. + T-cell responses associated with control of viremia. Science. 1997;278:1447-1450.
7. Wood E, Hogg RS, Harrigan PR, et al. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis. 2005;5 407-414.
8. Younes SA, Trautmann L, Yassine-Diab B, et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol. 2007;178:788-797.
9. Vora, S, Yerly, L, Kaiser, L, et al. Patients treated during primary HIV-1 infection: 5-year outcome [H-159]. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30,2002; San Diego, CA.
10. Stekler J, Maenza J, Stevens C, et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS. 2006;20:1269-1274.
11. Sabundayo BP, McArthur JH, Langan SJ, et al. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy. 2006;26: 674-681.
12. UCSD-AIEDRP Statistical and Coordinating Center. Acute infection and early disease research program (AIEDRP). 2007. Available at: http://www.aiedrp.org/. Accessed August 8, 2008.
13. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med. 2002;347:385-394.
14. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725-733.
15. Janssen RS, Satten GA, Strainer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
16. Guy RJ, Breschkin AM, Keenan CM, et al. Improving HIV surveillance in Victoria: the role of the "detuned" enzyme immunoassay. J Acquir Immune Defic Syndr. 2005;38:495-499.
17. McFarland W, Busch MP, Kellogg TA, et al. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr. 1999;22:484-489.
18. Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr. 2003;33:625-634.
19. Rutherford GW, Schwarcz SK, McFarland W Surveillance for incident HIV infection: new technology and new opportunities. J Acquir Immune Defic Syndr. 2000;25:S115-S119.
20. Machado DM, Delwart EL, Diaz RS et al. Use of the sensitive/less- sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS. 2002;16:113-119.
21. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS table for grading severity of adult adverse experiences, version 1.0 December 2004. Available at: http://rcc.tech-res.com/tox-tables.htm. Accessed August 08, 2008.
22. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
23. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
24. D'Arminio MA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14: 499-507.
25. Dorrucci M, Pezzotti P, Grisorio B, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS. 2001;15:1733-1736.
26. Bhaskaran K, and CASCADE Collaboration. Time to stopping or switching HAART initiated in primary HIV infection. Abstract THPE0105. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
27. Tan D, Shen S, Rau N, et al. Efficacy and time to discontinuation of first HAART regimens in antiretroviral (ARV) naive patients. Abstract CDB0487. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
28. Mingrone H, Porteiro N, Loiza E, et al. How many patients remain in their first regimen after 4 years of HAART? Abstract CDB0499. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
29. Wang SA, Panlilio AL, Doi PA, et al. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV postexposure prophylaxis registry. Infect Control Hosp Epidemiol. 2000;21:780-785.
30. Quirino T, Niero F, Ricci E, et al. HAART tolerablility: post-exposure prophylasis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther. 2000;5:195-197.
31. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352:1873-1883.
32. Lee S, Wood O, Taffs RE, et al. Development and evaluation of HIV-1 subtype RNA panels for the standardization of HIV-1 NAT assays. J Virol Methods. 2006;137:287-291.
33. McCormick MK, Dockter J, Linnen JM, et al. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA. J Clin Virol. 2006;36:166-176.
34. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951-959.
35. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, January 29, 2008. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf Accessed August 15, 2008.
36. Smith DE, Walker BD, Cooper DA, et al. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS. 2004;18:709-718.
37. Blankson JN. Primary HIV-1 infection: to treat or not to treat? AIDS Read. 2005;15:245-251.
38. Kassutto S, Maghsoudi K, Johnston MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006;42:1024-1031.
39. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005;191:1410-1418.
40. + T-cell responses associated with control of viremia. Science. 1997;278:1447-1450.
41. Wood E, Hogg RS, Harrigan PR, et al. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis. 2005;5 407-414.
42. Younes SA, Trautmann L, Yassine-Diab B, et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol. 2007;178:788-797.
43. Vora, S, Yerly, L, Kaiser, L, et al. Patients treated during primary HIV-1 infection: 5-year outcome [H-159]. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30,2002; San Diego, CA.
44. Stekler J, Maenza J, Stevens C, et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS. 2006;20:1269-1274.
45. Sabundayo BP, McArthur JH, Langan SJ, et al. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy. 2006;26: 674-681.
46. UCSD-AIEDRP Statistical and Coordinating Center. Acute infection and early disease research program (AIEDRP). 2007. Available at: http://www.aiedrp.org/. Accessed August 8, 2008.
47. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med. 2002;347:385-394.
48. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725-733.
49. Janssen RS, Satten GA, Strainer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
50. Guy RJ, Breschkin AM, Keenan CM, et al. Improving HIV surveillance in Victoria: the role of the "detuned" enzyme immunoassay. J Acquir Immune Defic Syndr. 2005;38:495-499.
51. McFarland W, Busch MP, Kellogg TA, et al. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr. 1999;22:484-489.
52. Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr. 2003;33:625-634.
53. Rutherford GW, Schwarcz SK, McFarland W Surveillance for incident HIV infection: new technology and new opportunities. J Acquir Immune Defic Syndr. 2000;25:S115-S119.
54. Machado DM, Delwart EL, Diaz RS et al. Use of the sensitive/less- sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS. 2002;16:113-119.
55. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS table for grading severity of adult adverse experiences, version 1.0 December 2004. Available at: http://rcc.tech-res.com/tox-tables.htm. Accessed August 08, 2008.
56. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
57. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
58. D'Arminio MA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14: 499-507.
59. Dorrucci M, Pezzotti P, Grisorio B, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS. 2001;15:1733-1736.
60. Bhaskaran K, and CASCADE Collaboration. Time to stopping or switching HAART initiated in primary HIV infection. Abstract THPE0105. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
61. Tan D, Shen S, Rau N, et al. Efficacy and time to discontinuation of first HAART regimens in antiretroviral (ARV) naive patients. Abstract CDB0487. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
62. Mingrone H, Porteiro N, Loiza E, et al. How many patients remain in their first regimen after 4 years of HAART? Abstract CDB0499. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
63. Wang SA, Panlilio AL, Doi PA, et al. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV postexposure prophylaxis registry. Infect Control Hosp Epidemiol. 2000;21:780-785.
64. Quirino T, Niero F, Ricci E, et al. HAART tolerablility: post-exposure prophylasis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther. 2000;5:195-197.
65. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352:1873-1883.
66. Lee S, Wood O, Taffs RE, et al. Development and evaluation of HIV-1 subtype RNA panels for the standardization of HIV-1 NAT assays. J Virol Methods. 2006;137:287-291.
67. McCormick MK, Dockter J, Linnen JM, et al. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA. J Clin Virol. 2006;36:166-176.
68. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951-959.